You might have seen one or both of these ingredient names on the label of a dietary supplement product, most likely for pre-workout, weight loss, brain health, or other performance enhancement. What are they? Are they the same thing? Are they safe? This article looks at rauwolscine and Rauwolfia—and how they appear on labels—so you can be aware of what you might be taking.

Rauwolfia and rauwolscine are not prohibited for use by Military Service Members, but products with these ingredients could impact your readiness.

What is Rauwolfia?

Rauwolfia is a group of plants that contain more than 30 chemical compounds, including the stimulants rauwolscine and yohimbine, as well as reserpine, which can be used as a drug. When you see Rauwolfia listed on a product label, it might contain any combination of the 30 chemicals that occur in the plant.

What is rauwolscine?

Rauwolscine is one of the many chemicals occurring in Rauwolfia plants. It can be extracted from these plants, but it also can be created in a laboratory. On dietary supplement labels, rauwolscine might be listed instead as alpha-yohimbine or α-yohimbine. Rauwolscine (despite its synonym “alpha yohimbine”) isn’t the same as yohimbine, but the two are very similar, and both are stimulants.

Are Rauwolfia and rauwolscine “safe” for Military Service Members to use?

Neither Rauwolfia nor rauwolscine is prohibited for use by Military Service Members, and neither should cause a positive result on a military drug test. However, products listing either or both ingredients are possibly unsafe, so you should be aware of what you are taking.

Animal studies suggest that Rauwolfia (or Rauvolfia) can affect a developing fetus and should not be used by children or pregant or nursing women. Human studies on Rauwolfia are old and somewhat conflicting, possibly due to the various chemical compounds (or combinations of chemicals) present in the plant. In fact, reserpine is rarely used as a prescription drug due to unwanted side effects, and yohimbine has been banned in many countries outside the U.S. because of its potential for serious health effects. In addition, the combination of unknown chemicals present in Rauwolfia might reduce blood pressure, resulting in dizziness, tiredness, irregular heartbeat, and breathlessness. Depression or worsening depression has also been associated with Rauwolfia.

No clinical studies on the safety or efficacy of rauwolscine have been reported, so we cannot be certain how safe or unsafe it is as a stimulant ingredient by itself.

Many dietary supplement products with rauwolscine or Rauwolfia—primarily weight-loss and pre-workout supplements—have been found to contain additional (sometimes hidden) stimulants, and their cumulative effects can be dangerous. This can lead to more serious adverse events than single ingredients themselves. For more information, please read the OPSS article about stimulants.

How can I tell which is in my supplement?

Look at the Supplement Facts label where the ingredients are listed. Depending on the wording, you might get an idea of what is in your supplement: Rauwolfia, rauwolscine, or both. Here are some examples of what you might see on a label and what each might mean.

  • If you see “Rauwolfia vomitoria root,” it could contain any combination of the many chemical compounds in Rauwolfia (some of which are stimulants).
  • If you see “extract”—such as “Rauwolfia serpentina extract”—there is no way to know which “extracted” chemical compounds are present (some of which might be stimulants).
  • If you see the word “rauwolscine” with the plant name Rauwolfia, such as “Rauwolscine (Rauwolfia vomitoria root bark extract)” or “Rauwolfia canescens root extract (alpha yohimbine),” it presumably doesn’t have any of the other chemicals from the plant, so the ingredient’s effects are those associated only with the stimulant rauwolscine.
  • A similar term found on labels is “Rauwolfia serpentina extract (leaf) (std. for 90% rauwolscine)” or the similar wording. This suggests that 10% of the other plant chemicals are present, such as yohimbine. This is important because yohimbine has been associated with some serious health risks.
  • Sometimes, just “rauwolscine” or “rauwolscine (alpha-yohimbine)” or “alpha yohimbine” is listed. In this case, presumably, none of the other Rauwolfia-based substances are present. It’s also possible to create this chemical substance in a laboratory, so you can’t tell if the ingredient is natural or synthetic.

So, not knowing the exact nature of an ingredient listed on a label makes it almost impossible to judge what kind of effects it might produce. The best way to know what’s in your supplement is to look for evidence of third-party certification or verification.


Updated 03 November 2020


Agrawal, S. N. (2019). Rauvolfia serpentina: A medicinal plant of exceptional qualities. Alternative Medicine & Chiropractic, 2(2), Article 180016.

Aquaisua, A. N., Mbadugha, C. C., Bassey, E. I., Ekong, M. B., Ekanem, T. B., & Akpanabiatu, M. I. (2017). Effects of Rauvolfia vomitoria on the cerebellar histology, body and brain weights of albino Wistar rats. Journal of Experimental and Clinical Anatomy, 16, 41–45.

Arambewela, L. S. R., & Madawela, G. (2008). Alkaloids from Rauvolfia canescens. Pharmaceutical Biology, 39(3), 239–240. doi:10.1076/phbi.

Asoro, I., Ebuehi, T., & Igwo-Ezikpe, N. (2018). Comparative toxicity studies of Rauwolfia vomitoria leaf and root extracts in Wistar rats. International Journal of Biochemistry Research & Review, 22(2), 1–10. doi:10.9734/ijbcrr/2018/41638

B. Ekong, M., & A. Nwakanma, A. (2017). Rauwolfia vomitoria and Gongronema latifolium extracts influences cerebellar cortex. Alzheimer's, Dementia & Cognitive Neurology, 1(3), 1–6. doi:10.15761/adcn.1000115

Biradar, N., Hazarika, I., & Chandy, V. (2016). Current insight to the uses of Rauwolfia: A review. Research & Reviews: A Journal of Pharmacognosy, 3(3), 1–4.

Bunkar, A. R. (2017). Therapeutic uses of Rauwolfia serpentina. International Journal of Advanced Science and Research, 2(2), 23–26.

Callahan, M. F., Beales, M., & Oltmans, G. A. (1984). Yohimbine and rauwolscine reduce food intake of genetically obese (obob) and lean mice. Pharmacology Biochemistry and Behavior, 20(4), 591–599. doi:10.1016/0091-3057(84)90309-5

Cohen, P. A., Wang, Y. H., Maller, G., DeSouza, R., & Khan, I. A. (2015). Pharmaceutical quantities of yohimbine found in dietary supplements in the USA. Drug Testing and Analysis, 8(3-4), 357–369. doi:10.1002/dta.1849

Das1, S., Saraf, A., Sharma, D., Raja, W., & Sohal, J. K. (2019). Qualitative screening of bioactive secondary metabolites present in Withania somnifera and Rauwolfia serpentina root and stem extracts with pharmacological importance. International Journal of Research and Analytical Reviews, 6(2), 69–74.

Doxey, J. C., Lane, A. C., Roach, A. G., & Virdce, N. K. (1984). Comparison of the α-adrenoceptor antagonist profiles of idazoxan (RX 781094), yohimbine, rauwolscine and corynanthine. Naunyn-Schmiedeberg's Archives of Pharmacology, 325(2), 136–144. doi:10.1007/bf00506193

Garg, N. K., Sharma, R. P., Nagar, J., Trivedi, P., & Pareek, A. (2018). Role of sarpgandha (Rauwolfia serpentina) in management of hypertension. Journal of Ayurveda, 12(3), 129–133.

Ghate, V. U., Gajendragadkar, M. P., & Jadhav, A. B. (2019). Review of Rauvolfia serpentina(L.) Benth.exKurz. International Journal of Research, 8(6), 414–421.

Godfraind, T., Miller, R. C., & Lima, J. S. (1983). Effects of yohimbine, rauwolscine and corynanthine on contractions and calcium fluxes induced by depolarization and prostaglandin F2α in rat aorta. British Journal of Pharmacology, 80(1), 115–121. doi:10.1111/j.1476-5381.1983.tb11056.x

James-Yi, S. A., Hilmas, C. J., & Fabricant, D. S. (2019). Risk assessment, regulation, and the role of biomarkers for the evaluation of dietary ingredients present in dietary supplements. In R. C. Gupta (Ed.), Biomarkers in Toxicology (2nd ed., pp. 693–714). London, UK: Elsevier.

Kad, A., Pundir, A., Sharma, S., & Sood, H. (2017). Development of suspension cultures and ex-vitro rooting in Rauwolfia serpentina for rapid and large scale multiplication. International Journal of Innovative Research in science and Engineering, 3(1), 135–143.

Kanyal, N. (2016). Role of Rauwolfia serpentina in stroke induced experimental dementia. Indian Journal of Pharmaceutical and Biological Research, 4(1), 19–30. doi:10.30750/ijpbr.4.1.3

Kohli, J. D., & De, N. N. (1956). Pharmacological action of rauwolscine. Nature, 177(4521), 1182. doi:10.1038/1771182a0

Kumar, S. (2016). Homeopathic medicine Rauwolfia serpentina ameliorate blood pressure and oxidative stress parameters of kidney by modulating expression of antioxidant enzymes in deoxycorticosterone acetate (DOCA)-salt-induced hypertensive rat model. Journal of Drug Research and Development, 2(1), Article 111. doi:10.16966/2470-1009.111

Lanier, S. M., Graham, R. M., Hess, H. J., Grodski, A., Repaske, M. G., Nunnari, J. M., . . . Homcy, C. J. (1987). Synthesis and characterization of arylamine derivatives of rauwolscine as molecular probes for α2-adrenergic receptors. Hypertension, 9(6 pt 2), 120–124. doi:10.1161/01.HYP.9.6_Pt_2.III120

Levy, B., & Koelle, G. B. (1958). The cardiovascular and respiratory actions of rauwolscine. Journal of Pharmacology and Experimental Therapeutics, 123(4), 278–286.

Lobay, D. (2015). Rauwolfia in the treatment of hypertension. Integrative Medicine, 14(3), 40–46.

Mallick, S. R., Jena, R. C., & Samal, K. C. (2012). Rapid in vitro multiplication of an endangered medicinal plant sarpgandha (Rauwolfia serpentina). American Journal of Plant Sciences, 03(04), 437–442. doi:10.4236/ajps.2012.34053

Md. Harun Ar, R., Chandan Kumar, D., Sheikh Shamimul, A., & Syeda Sharmeen, S. (2019). Differential chromosome banding of three Rauvolfia species. Cytologia, 84(2), 143–146. doi:10.1508/cytologia.84.143

MedlinePlus. (2019). Reserpine. Retrieved 20 May 2020 from

Miller, E. R., Hovey, M. T., & Scheidt, K. A. (2020). A concise, enantioselective approach for the synthesis of yohimbine alkaloids. Journal of the American Chemical Society, 142(5), 2187–2192. doi:10.1021/jacs.9b12319

Mukherjee, E., Gantait, S., Kundu, S., Sarkar, S., & Bhattacharyya, S. (2019). Biotechnological interventions on the genus Rauvolfia: Recent trends and imminent prospects. Applied Microbiology and Biotechnology, 103(18), 7325–7354. doi:10.1007/s00253-019-10035-6

Mukherjee, J. N. (1953). Effect of rauwolscine on the action of adrenaline on blood pressure. Nature, 172(4384), 867–867. doi:10.1038/172867a0

Okereke, S. C., Ijeh, I. I., & Arunsi, U. O. (2017). Determination of bioactive constituents of Rauwolfia vomitoria Afzel (Asofeyeje) roots using gas chromatography-mass spectrometry (GC-MS) and Fourier transform infrared spectrometry (FT-IR). African Journal of Pharmacy and Pharmacology, 11(2), 25–31. doi:10.5897/ajpp2016.4712

Pimoule, C., Briley, M. S., Gay, C., Loo, H., Sechter, D., Zarifian, E., . . . Langer, S. Z. (1983). 3H-rauwolscine binding in platelets from depressed patients and healthy volunteers. Psychopharmacology, 79(4), 308–312. doi:10.1007/bf00433407

Raman, V., Avula, B., Galal, A. M., Wang, Y.-H., & Khan, I. A. (2012). Microscopic and UPLC–UV–MS analyses of authentic and commercial yohimbe (Pausinystalia johimbe) bark samples. Journal of Natural Medicines, 67(1), 42–50. doi:10.1007/s11418-012-0642-2

Rockhold, R. W., & Gross, F. (1981). Yohimbine diastereoisomers: Cardiovascular effects after central and peripheral application in the rat. Naunyn-Schmiedeberg's Archives of Pharmacology, 315(3), 227–231. doi:10.1007/bf00499839

Rohela, G. K., Bylla, P., Korra, R., & Reuben, C. (2016). Phytochemical screening and antimicrobial activity of leaf, stem, root and their callus extracts in Rauwolfia tetraphylla. International Journal of Agriculture and Biology, 18(03), 521–528. doi:10.17957/ijab/15.0120

Sagi, S., Avula, B., Wang, Y.-H., & Khan, I. A. (2015). Quantification and characterization of alkaloids from roots of Rauwolfia serpentina using ultra-high performance liquid chromatography-photo diode array-mass spectrometry. Analytical and Bioanalytical Chemistry, 408(1), 177–190. doi:10.1007/s00216-015-9093-4

Shamon, S. D., & Perez, M. I. (2016). Blood pressure-lowering efficacy of reserpine for primary hypertension. Cochrane Database of Systematic Reviews, 2016(12), Article CD007655. doi:10.1002/14651858.CD007655.pub3

Singh, H. K., Prakash, I., Kumar, V., Gupta, S., & Charan, A. A. (2016). Antifungal activity of methanolic and ethanolic leaf extracts of medicinal plants. International Journal of Plant Protection, 9(2), 474–478. doi:10.15740/has/ijpp/9.2/474-478

Slim, H. B., Black, H. R., & Thompson, P. D. (2011). Older blood pressure medications—Do they still have a place? The American Journal of Cardiology, 108(2), 308–316. doi:10.1016/j.amjcard.2011.03.041

Soni, R., Jaiswal, S., Bara, J. K., & Saksena, P. (2016). The use of Rauwolfia serpentina in hypertensive patients. Journal of Biotechnology and Biochemistry, 2(5), 28–32.

Timmermans, P. B. M. W. M., van Meel, J. C. A., & van Zwieten, P. A. (1983). Calcium antagonists and α-receptors. European Heart Journal, 4(suppl C), 11–17. doi:10.1093/eurheartj/4.suppl_C.11

Tlhapi, D., Ramaite, I., Van Ree, T., Anokwuru, C., Orazio, T.-S., & Hoppe, H. (2018). Isolation, chemical profile and antimalarial activities of bioactive compounds from Rauvolfia caffra Sond. Molecules, 24(1), Article 39. doi:10.3390/molecules24010039

Verma, R., Hanif, K., Sasmal, D., & Raghubir, R. (2010). Resurgence of herbal antihypertensives in management of hypertension. Current Hypertension Reviews, 6(3), 190–198. doi:10.2174/157340210791936705

Zwieten, P. A., Thoolen, M. J. M. C., & Timmermans, P. B. M. W. M. (1983). The pharmacology of centrally acting antihypertensive drugs. British Journal of Clinical Pharmacology, 15(Supplement S4), 455S–462S. doi:10.1111/j.1365-2125.1983.tb00311.x